Skip to main content
. 2022 May 19;8(7):1010–1018. doi: 10.1001/jamaoncol.2022.1059

Figure 2. CONSORT Diagram of the GeparX Study.

Figure 2.

AE indicates adverse event; CT, chemotherapy; Dmab, denosumab; EC, epirubicin and cyclophosphamide; nP, nab-paclitaxel; wk, weekly.

aThree patients did not start Dmab and were analyzed for safety and adherence in no Dmab arm; in 7 patients of nP d1,8 q3 wk arm, there was no pause at day 15 in at least 2 cycles, and they were analyzed for safety and adherence in the nP weekly arm.

bIncludes patients who completed both nP and EC.

cOf patients “as randomized.”